Noa Therapeutics Inc. (Noa) is a preclinical Canadian biotech company aiming to defy the convention of traditional drug development to revolutionize treatment options for those living with complex inflammatory skin diseases. Leveraging intelligent design, Noa is pioneering the development of multimodal therapeutics; a singularly radical approach to address unmet needs and unlock opportunities within underserved and untapped markets. Targeting a first use case in atopic dermatitis, Noa’s non-steroidal small molecules aim to simultaneously addressing three constructive therapeutic targets. Through this multilateral approach, Noa strives to provide meaningful outcomes and establish a new, inclusive, standard for the first-line-treatment of inflammatory skin disease.